Last reviewed · How we verify
Cliquinol (CLIOQUINOL)
At a glance
| Generic name | CLIOQUINOL |
|---|---|
| Drug class | Standardized Chemical Allergen [EPC] |
| Target | Amyloid beta A4 protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1934 |
Approved indications
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
Key clinical trials
- Improvement of Psoriasis Patients' Adherence to Topical Drugs (NA)
- Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study (PHASE2)
- Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
- Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous (PHASE3)
- Magen Haim Project - Assessing Hand Hygiene Formulas (PHASE4)
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cliquinol CI brief — competitive landscape report
- Cliquinol updates RSS · CI watch RSS